Exact Sciences Acquired by Abbott — Healthcare M&A

Abbott has completed its acquisition of Exact Sciences in a deal valued at $21 billion, bringing the diagnostics imaging and molecular testing business into the Abbott portfolio. Following the transaction, Exact Sciences has been delisted from Nasdaq, marking the end of its independent public-company status. The acquisition is structured as a merger and is now closed.

Exact Sciences is known for developing and commercializing cancer screening tests, including colorectal cancer diagnostics, while Abbott operates across healthcare with a focus on diagnostics and medical technologies. The combination strengthens Abbott’s position in oncology screening and expands its capabilities across the diagnostics workflow, from testing to downstream clinical decision support. For the market, the transaction signals continued consolidation in healthcare diagnostics as large strategic players seek scale and growth in high-demand screening categories.

While the announcement confirms the $21 billion purchase price and the closing status, additional deal mechanics such as specific consideration mix and any remaining regulatory milestones were not detailed here. Abbott’s completion of the acquisition also removes Exact Sciences’ equity from public trading, consolidating exposure to its screening franchise within a strategic buyer’s broader diagnostics platform.